Current and historical daily PE Ratio for Calithera Biosciences Inc (
STU:2CB0
) from 2014 to May 24 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Calithera Biosciences stock (STU:2CB0) PE ratio as of May 24 2024 is 0.
More Details
Calithera Biosciences Inc (STU:2CB0) PE Ratio (TTM) Chart
Calithera Biosciences Inc (STU:2CB0) PE Ratio (TTM) Historical Data
View and export this data going back to 2014. Start your Free Trial
Total 943
- 1
- 2
- 3
- 4
- 5
- 6
- 11
| Calithera Biosciences PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-05-24 | At Loss | 2022-12-13 | At Loss |
| 2023-02-15 | At Loss | 2022-12-12 | At Loss |
| 2023-02-14 | At Loss | 2022-12-09 | At Loss |
| 2023-02-13 | At Loss | 2022-12-08 | At Loss |
| 2023-02-10 | At Loss | 2022-12-07 | At Loss |
| 2023-02-09 | At Loss | 2022-12-06 | At Loss |
| 2023-02-08 | At Loss | 2022-12-05 | At Loss |
| 2023-02-07 | At Loss | 2022-12-02 | At Loss |
| 2023-02-06 | At Loss | 2022-12-01 | At Loss |
| 2023-02-03 | At Loss | 2022-11-30 | At Loss |
| 2023-02-02 | At Loss | 2022-11-29 | At Loss |
| 2023-02-01 | At Loss | 2022-11-28 | At Loss |
| 2023-01-30 | At Loss | 2022-11-25 | At Loss |
| 2023-01-27 | At Loss | 2022-11-24 | At Loss |
| 2023-01-26 | At Loss | 2022-11-23 | At Loss |
| 2023-01-25 | At Loss | 2022-11-22 | At Loss |
| 2023-01-24 | At Loss | 2022-11-21 | At Loss |
| 2023-01-23 | At Loss | 2022-11-18 | At Loss |
| 2023-01-20 | At Loss | 2022-11-17 | At Loss |
| 2023-01-19 | At Loss | 2022-11-16 | At Loss |
| 2023-01-18 | At Loss | 2022-11-15 | At Loss |
| 2023-01-17 | At Loss | 2022-11-14 | At Loss |
| 2023-01-16 | At Loss | 2022-11-11 | At Loss |
| 2023-01-13 | At Loss | 2022-11-10 | At Loss |
| 2023-01-12 | At Loss | 2022-11-09 | At Loss |
| 2023-01-11 | At Loss | 2022-11-08 | At Loss |
| 2023-01-10 | At Loss | 2022-11-07 | At Loss |
| 2023-01-09 | At Loss | 2022-11-04 | At Loss |
| 2023-01-06 | At Loss | 2022-11-03 | At Loss |
| 2023-01-05 | At Loss | 2022-11-02 | At Loss |
| 2023-01-04 | At Loss | 2022-11-01 | At Loss |
| 2023-01-03 | At Loss | 2022-10-28 | At Loss |
| 2023-01-02 | At Loss | 2022-10-27 | At Loss |
| 2022-12-30 | At Loss | 2022-10-26 | At Loss |
| 2022-12-29 | At Loss | 2022-10-25 | At Loss |
| 2022-12-28 | At Loss | 2022-10-24 | At Loss |
| 2022-12-27 | At Loss | 2022-10-21 | At Loss |
| 2022-12-23 | At Loss | 2022-10-20 | At Loss |
| 2022-12-22 | At Loss | 2022-10-19 | At Loss |
| 2022-12-21 | At Loss | 2022-10-18 | At Loss |
| 2022-12-20 | At Loss | 2022-10-17 | At Loss |
| 2022-12-19 | At Loss | 2022-10-14 | At Loss |
| 2022-12-16 | At Loss | 2022-10-13 | At Loss |
| 2022-12-15 | At Loss | 2022-10-12 | At Loss |
| 2022-12-14 | At Loss | 2022-10-11 | At Loss |
Calithera Biosciences Inc (STU:2CB0) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Calithera Biosciences Inc
NAICS : 325412
SIC : 2834
ISIN : US13089P1012
Description
Calithera Biosciences Inc is a clinical-stage pharmaceutical company. The business activity of the firm functions through the region of the United States. It focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. Its product candidate is CB-839, an inhibitor of glutaminase for the treatment of solid tumors. Its other product candidate, CB-1158, is being developed for hematology and oncology indications.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers